The epilepsy drug topiramate may provide long-term benefits for people with binge-eating disorder and obesity, as suggested by results of a small study from the University of Cincinnati College of Medicine. The study included 61 subjects randomly selected to receive topiramate or placebo; 44 patients received topiramate, and results were available for 43 of these patients, who reached an ending dosage of 250 mg/d. All 43 patients experienced a significant decline in the number of weekly binge-eating episodes, and they experienced a significant weight loss as well. Based on these results, the study team concluded that further studies of topiramate for the long-term treatment of binge-eating disorder are needed.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs